Clinical Utility and Interpretation of CKD Stages in Living Kidney Donors

    loading  Checking for direct PDF access through Ovid

Abstract

Methods

Using national registry data from the United States (SRTR), we studied end-stage renal disease (ESRD) risk in 67,571 LKDs 1999-2015 with at least one postdonation serum creatinine (SCr) reported to the registry. We calculated eGFR using the CKD-EPI equation. Measurements with eGFR<15 were excluded from analysis. Donors were followed through 16 years post-donation or administrative censorship on 12/31/2015. We modeled the association between eGFR category (≥60, 45-59, 30-44, 15-30, corresponding to no CKD, CKD stage 3, stage 4A, and stage 4B) using Cox regression with eGFR category as a time-varying exposure and adjusting for donor age, sex, race (black vs nonblack), BMI, and 1st-degree biological relationship to recipient.

Results

A total of 117,051 CKD measurements were reported at median (IQR) 11 (4-14) months post-donation (90th percentile 25 months post-donation). Of these, 33.9% were in the range 45-59, 5.7% were in the range 30-45, and 0.8% were in the range 15-29. In an unadjusted model, eGFR 30-45 was associated with 3.9-fold higher risk of ESRD compared to donors with eGFR≥60 (HR=1.80 3.94 8.60, p<0.01) and eGFR 15-29 was associated with 40-fold higher risk (HR=5.41 40.29 299.77, p<0.001) (Table). After adjustment, these associations persisted with 5.3-fold higher risk for eGFR 30-45 (aHR=2.11 5.30 13.26, p< .001) and 54-fold higher risk for eGFR 15-29 (aHR=6.83 53.66 421.32, p<0.001). Donors with eGFR 45-60 had elevated risk but the association was not statistically significant (unadjusted HR=0.81 1.50 2.79, p=0.2; aHR=0.92 1.86 3.77, p=0.08).

Conclusions

Associations between eGFR category and subsequent ESRD risk are less strong in LKDs than in the general population, and the categorization of eGFR 45-60 as "CKD stage 3" may not be clinically meaningful among LKDs. Nevertheless, eGFR category is associated with subsequent ESRD risk among donors with eGFR<30, and our results support current guidelines recommending longitudinal followup of renal function in living kidney donors.

Conclusions

NIDDK R01DK096008 (Segev). NIDDK K01DK101677 (Massie).

Related Topics

    loading  Loading Related Articles